BerGenBio

BerGenBio: BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
COVID-19, Fibrosis, Infectious Disease, Oncology
Finance
Pre-Revenues
Investement Strategy
Under the Radar
Listing
Europe, Public
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
Jonas Lies vei 91
Bergen, Hordaland 5009
Norway

Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls

  • Richard Godfrey, CEO

Lead Programs

Bemcentinib

Indication Phase
NSCLC 2
NSCLC 2
NSCLC 2
TNBC 2
Melanoma 2
AML 2

BGB149

Indication Phase
Cancer 1

Top 10 Holders of BerGenBio ASA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Nordea Investment Management AB (Norway) 8.18 4,997,462 20.53 Stakes 11/4/20
Alfred Berg Kapitalforvaltning AS 6.21 3,793,133 15.58 Stakes 11/4/20
Fjärde AP-fonden 4.31 2,633,298 10.82 Stakes 11/4/20
MP Pensjon PK 2.58 1,572,983 6.46 Stakes 11/4/20
KLP Kapitalforvaltning AS 2.52 1,540,000 6.33 Stakes 11/4/20
Rhenman & Partners Asset Management AB 1.26 1,097,993 4.51 Funds 6/30/20
First Fondene AS 0.60 520,039 2.14 Funds 6/30/20
DNB Asset Management AS 0.65 398,828 1.64 Funds 10/30/20
Storebrand Asset Management AS 0.52 319,383 1.31 Funds 11/30/20
RAM Active Investments SA 0.26 229,588 0.94 Funds 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.